MX2017016437A - Metodos de purificacion y/o inactivacion viral. - Google Patents

Metodos de purificacion y/o inactivacion viral.

Info

Publication number
MX2017016437A
MX2017016437A MX2017016437A MX2017016437A MX2017016437A MX 2017016437 A MX2017016437 A MX 2017016437A MX 2017016437 A MX2017016437 A MX 2017016437A MX 2017016437 A MX2017016437 A MX 2017016437A MX 2017016437 A MX2017016437 A MX 2017016437A
Authority
MX
Mexico
Prior art keywords
purification
methods
viral inactivation
glycoprotein
protein
Prior art date
Application number
MX2017016437A
Other languages
English (en)
Other versions
MX381279B (es
Inventor
AHARONOV Jenny
EREZ Elinor
Harosh Eli
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of MX2017016437A publication Critical patent/MX2017016437A/es
Publication of MX381279B publication Critical patent/MX381279B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/32—Bonded phase chromatography
    • B01D15/325—Reversed phase
    • B01D15/327—Reversed phase with hydrophobic interaction
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D21/00—Separation of suspended solid particles from liquids by sedimentation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D39/00—Filtering material for liquid or gaseous fluids
    • B01D39/14—Other self-supporting filtering material ; Other filtering material
    • B01D39/20—Other self-supporting filtering material ; Other filtering material of inorganic material, e.g. asbestos paper, metallic filtering material of non-woven wires
    • B01D39/2003—Glass or glassy material
    • B01D39/2017—Glass or glassy material the material being filamentary or fibrous
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/145—Ultrafiltration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Water Supply & Treatment (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Geology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Métodos de purificación y/o desactivación viral de una proteína (por ejemplo, glicoproteína) que comprenden un paso de tratamiento de la proteína (por ejemplo, glicoproteína) con una combinación de ácido caprílico y etanol.
MX2017016437A 2015-06-26 2016-06-24 Métodos de purificación y/o inactivación viral. MX381279B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15174029 2015-06-26
PCT/EP2016/064668 WO2016207353A1 (en) 2015-06-26 2016-06-24 Methods of purification and/or viral inactivation

Publications (2)

Publication Number Publication Date
MX2017016437A true MX2017016437A (es) 2018-03-02
MX381279B MX381279B (es) 2025-03-12

Family

ID=53510646

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017016437A MX381279B (es) 2015-06-26 2016-06-24 Métodos de purificación y/o inactivación viral.

Country Status (15)

Country Link
US (1) US10906953B2 (es)
EP (2) EP3313859B1 (es)
JP (2) JP6845813B2 (es)
KR (1) KR102714934B1 (es)
CN (3) CN122541502A (es)
AU (1) AU2016282916B2 (es)
CA (1) CA2990311A1 (es)
CL (1) CL2017003309A1 (es)
CO (1) CO2018000171A2 (es)
ES (1) ES2770860T3 (es)
MX (1) MX381279B (es)
MY (1) MY179524A (es)
PH (1) PH12017502386A1 (es)
RU (1) RU2719468C2 (es)
WO (1) WO2016207353A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3973982T1 (sl) 2017-09-01 2024-10-30 Ferring B. V. Sestavek za nadzorovano stimulacijo jajčnikov
CN110305903B (zh) * 2019-07-31 2021-10-01 江苏璟泽生物医药有限公司 重组人促卵泡激素及其制备方法
CN110563832B (zh) * 2019-07-31 2025-11-14 江苏璟泽生物医药有限公司 一种高纯度重组促卵泡刺激素纯化方法
KR200493431Y1 (ko) 2019-10-23 2021-03-29 (주)에르젠아웃도어 다기능 캠핑용 타프
CN116457081A (zh) * 2020-10-19 2023-07-18 赛多利斯层析设备 用于纯化生物分子的设备和方法
EP4778935A1 (en) * 2025-01-15 2026-07-22 Sartorius Stedim Biotech GmbH Method for purifying a target product

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1311764A (fr) 1959-12-29 1962-12-14 Procédé de purification de la gonadotropine folliculo-stimulante
FR2580503B1 (fr) 1985-04-23 1988-02-19 Limousin Inst Bio Perfectionnements apportes a la preparation des inhibiteurs de l'adhesion cellulaire, anti-adhesines ainsi obtenues et medicaments et aliments les contenant
US4939176A (en) * 1988-12-20 1990-07-03 Miles Inc. Viral inactivation process
DE69133399T2 (de) * 1990-04-19 2005-06-30 Bayer Corp. Methode zur Herstellung von im Wesentlichen monomeren normalen menschlichen Serum-Albumin
US5561115A (en) * 1994-08-10 1996-10-01 Bayer Corporation Low temperature albumin fractionation using sodium caprylate as a partitioning agent
WO2000056768A2 (en) * 1999-03-19 2000-09-28 Bayer Corporation Chromatographic albumin process
SI1654284T1 (sl) * 2003-08-12 2009-10-31 Octapharma Ag Postopek za pripravo alfa-1-antitripsinske raztopine
TWI488640B (zh) * 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
CN101397339B (zh) 2008-09-24 2012-07-25 上海天伟生物制药有限公司 糖蛋白中去除/灭活病毒的方法
TWI532495B (zh) 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2719704B1 (en) * 2011-04-08 2016-07-20 Universidad De Costa Rica Method for producing injectable formulations of blood-derived protein materials, and materials obtained using said method
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
CN103275206B (zh) * 2013-03-17 2014-09-10 赤峰博恩药业有限公司 孕马血清促性腺激素的提纯方法
WO2015056237A2 (en) 2013-10-18 2015-04-23 Universität Für Bodenkultur Wien Purification of proteins

Also Published As

Publication number Publication date
JP6845813B2 (ja) 2021-03-24
CL2017003309A1 (es) 2018-04-20
MY179524A (en) 2020-11-10
CA2990311A1 (en) 2016-12-29
EP3313859A1 (en) 2018-05-02
EP3313859B1 (en) 2019-11-20
RU2719468C2 (ru) 2020-04-17
KR20180020982A (ko) 2018-02-28
JP7061654B2 (ja) 2022-04-28
CN115028675A (zh) 2022-09-09
PH12017502386B1 (en) 2018-06-25
MX381279B (es) 2025-03-12
CN107709350A (zh) 2018-02-16
PH12017502386A1 (en) 2018-06-25
AU2016282916A1 (en) 2017-12-21
KR102714934B1 (ko) 2024-10-07
US20190002518A1 (en) 2019-01-03
JP2021036876A (ja) 2021-03-11
ES2770860T3 (es) 2020-07-03
WO2016207353A1 (en) 2016-12-29
RU2017145983A3 (es) 2019-09-05
US10906953B2 (en) 2021-02-02
CN122541502A (zh) 2026-08-11
CO2018000171A2 (es) 2018-04-30
RU2017145983A (ru) 2019-07-29
JP2018521049A (ja) 2018-08-02
EP3628675A1 (en) 2020-04-01
AU2016282916B2 (en) 2022-01-20
HK1253557A1 (en) 2019-06-21

Similar Documents

Publication Publication Date Title
CY1124921T1 (el) Μεθοδοι για την εκχυλιση και τον καθαρισμο μη μετουσιωμενων πρωτεϊνων
CO2018000171A2 (es) Metodos de purificacion y/o inactividad viral
CL2023001550A1 (es) Sistemas activos dinámicos acromosómicos.
CL2018002334A1 (es) Moduladores de complementos factor b (divisional solicitud 201600606)
MX2022015257A (es) Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas.
CL2018000684A1 (es) Moduladores de la proteína de núcleo de la hepatitis b.
MX2018008346A (es) Terapia de combinación de virus oncológico e inhibidor de punto de control.
CL2017000285A1 (es) Terapia combinada para el tratamiento de un paramixovirus
MX383652B (es) Moduladores de la vía de estrés integrada.
CL2016000493A1 (es) Inhibidores de polimerasa hcv.
MX2017010933A (es) Compuestos antivirales.
DK3134094T3 (da) Anordning til behandling af, behandling af komplikationer som følge af og/eller forebyggelse af luftvejssygdomme forårsaget af infektioner med bakterier, virus, protozoer, svampe og/eller mikrober, (...)
MX2017008277A (es) Solucion oftalmica acuosa.
BR112018073238A2 (pt) vírus oncolíticos compreendendo esrage e métodos de tratamento de câncer
CU24580B1 (es) Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas
WO2014152946A3 (en) Polypeptides for treating and/or limiting influenza infection
EP4480577A3 (en) Structured elements and methods of use
WO2020055858A8 (en) Pyridopyrazine and pyridotriazine inhibitors of influenza virus replication
PL3781401T3 (pl) System drukowania do druku na podłożu, oraz sposób eksploatacji systemu drukowania
MX378873B (es) Virus de sindrome reproductivo y respiratorio porcino (prrsv) que no ocurre de manera natural y metodos para usarlo.
BR112017000922A2 (pt) métodos e composições para tratar distúrbios relacionados ao hiv
MX2021004215A (es) Combinaciones de inhibidores de la replicación del virus de la gripe.
CL2016001977A1 (es) Composición que comprende igm derivada de plasma y su uso para el tratamiento o prevención de afecciones inmunitarias.
CL2018001666A1 (es) Dispositivo de filtro
BR112017024786A2 (pt) virus oncolíticos recombinantes e usos dos mesmos